Development of Drugs and Technology for Radiation Theragnosis

Nuclear Engineering and Technology

Volumn 48, Issue 3, 2016, Pages 597-607

  Jeong, Hwan Jeong ^a   Lee, Byung Chul ^b,c   Ahn, Byeong Cheol ^d   Kang, Keon Wook ^e  

^a Chonbuk National University Medical School   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Albumin; Cell Therapy; Molecular Imaging; Nanoparticles; Nuclear Medicine; Peptides; Radiation Theragnosis

Indexed keywords

EID: 84973338564     PISSN: 17385733     EISSN: 2234358X     Source Type: Journal    
DOI: 10.1016/j.net.2016.04.003     Document Type: Article

References (82)

1. Krenning E.P., Bakker W.H., Breeman W.A., Koper J.W., Kooij P.P., Ausema L., Lameris J.S., Reubi J.C., Lamberts S.W. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989, 1:242-244.
2. Rufini V., Calcagni M.L., Baum R.P. Imaging of neuroendocrine tumors. Semin. Nucl. Med. 2006, 36:228-247.
3. Decristoforo C., Mather S.J. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Bioconjug. Chem. 1999, 10:431-438.
4. Angeletti S., Corleto V.D., Schillaci O., Marignani M., Annibale B., Moretti A., Silecchia G., Scopinaro F., Basso N., Bordi C., Delle Fave G. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998, 42:792-794.
5. Leners N., Jamar F., Fiasse R., Ferrant A., Pauwels S. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma. J. Nucl. Med. 1996, 37:916-922.
6. Prasad V., Baum R.P. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q. J. Nucl. Med. Mol. Imaging 2010, 54:61-67.
7. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., Kooij P.P., de Herder W.W., Feelders R.A., van Eijck C.H., Esser J.P., Kam B.L., Krenning E.P. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005, 23:2754-2762.
8. Kaltsas G.A., Papadogias D., Makras P., Grossman A.B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr. Relat. Cancer 2005, 12:683-699.
9. Bison S.M., Konijnenberg M.W., Melis M., Pool S.E., Bernsen M.R., Teunissen J.J., Kwekkeboom D.J., de Jong M. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin. Transl. Imaging 2014, 2:55-66.
10. Graf F., Fahrer J., Maus S., Morgenstern A., Bruchertseifer F., Venkatachalam S., Fottner C., Weber M.M., Huelsenbeck J., Schreckenberger M., Kaina B., Miederer M. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS One 2014, 9:e88239.
11. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003, 24:389-427.
12. Dimitrakopoulou-Strauss A., Hohenberger P., Haberkorn U., Macke H.R., Eisenhut M., Strauss L.G. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J. Nucl. Med. 2007, 48:1245-1250.
13. Dimitrakopoulou-Strauss A., Seiz M., Tuettenberg J., Schmieder K., Eisenhut M., Haberkorn U., Strauss L.G. Pharmacokinetic studies of (6)(8)Ga-labeled Bombesin ((6)(8)Ga-BZH(3)) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin. Nucl. Med. 2011, 36:101-108.
14. Kahkonen E., Jambor I., Kemppainen J., Lehtio K., Gronroos T.J., Kuisma A., Luoto P., Sipila H.J., Tolvanen T., Alanen K., Silen J., Kallajoki M., Roivainen A., Schafer N., Schibli R., Dragic M., Johayem A., Valencia R., Borkowski S., Minn H. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin. Cancer Res. 2013, 19:5434-5443.
15. Sah B.R., Burger I.A., Schibli R., Friebe M., Dinkelborg L., Graham K., Borkowski S., Bacher-Stier C., Valencia R., Srinivasan A., Hany T.F., Mu L., Wild P.J., Schaefer N.G. Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J. Nucl. Med. 2015, 56:372-378.
16. Chatalic K.L., Franssen G.M., van Weerden W.M., McBride W.J., Laverman P., de Blois E., Hajjaj B., Brunel L., Goldenberg D.M., Fehrentz J.A., Martinez J., Boerman O.C., de Jong M. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J. Nucl. Med. 2014, 55:2050-2056.
17. 68Ga-labeled bombesin analog for gastrin-releasing peptide receptor-expressing prostate tumor imaging. Adv. Tech. Biol. Med. 2015, 3:135.
18. Schubiger P.A., Allemann-Tannahill L., Egli A., Schibli R., Alberto R., Carrel-Remy N., Willmann M., Blauenstein P., Tourwe D. Catabolism of neurotensins. Implications for the design of radiolabeling strategies of peptides. Q. J. Nucl. Med. 1999, 43:155-158.
19. Buchegger F., Bonvin F., Kosinski M., Schaffland A.O., Prior J., Reubi J.C., Blauenstein P., Tourwe D., Garcia Garayoa E., Bischof Delaloye A. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J. Nucl. Med. 2003, 44:1649-1654.
20. Garcia-Garayoa E., Blauenstein P., Blanc A., Maes V., Tourwe D., Schubiger P.A. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:37-47.
21. Brans B., Linden O., Giammarile F., Tennvall J., Punt C. Clinical applications of newer radionuclide therapies. Eur. J. Cancer 2006, 42:994-1003.
22. Froberg A.C., de Jong M., Nock B.A., Breeman W.A., Erion J.L., Maina T., Verdijsseldonck M., de Herder W.W., van der Lugt A., Kooij P.P., Krenning E.P. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma, Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1265-1272.
23. Wild D., Behe M., Wicki A., Storch D., Waser B., Gotthardt M., Keil B., Christofori G., Reubi J.C., Macke H.R. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J. Nucl. Med. 2006, 47:2025-2033.
24. Wild D., Macke H., Christ E., Gloor B., Reubi J.C. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N. Engl. J. Med. 2008, 359:766-768.
25. Christ E., Wild D., Forrer F., Brandle M., Sahli R., Clerici T., Gloor B., Martius F., Maecke H., Reubi J.C. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 2009, 94:4398-4405.
26. Haubner R., Weber W.A., Beer A.J., Vabuliene E., Reim D., Sarbia M., Becker K.F., Goebel M., Hein R., Wester H.J., Kessler H., Schwaiger M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005, 2:e70.
27. Janssen M., Frielink C., Dijkgraaf I., Oyen W., Edwards D.S., Liu S., Rajopadhye M., Massuger L., Corstens F., Boerman O. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother. Radiopharm. 2004, 19:399-404.
28. 188Re chelated iminodiacetate core: highly enhanced uptake and excretion kinetics of theragnosiss against tumor angiogenesis. RSC Adv. 2013, 3:782-792.
29. Yoo J.S., Lee J., Jung J.H., Moon B.S., Kim S., Lee B.C., Kim S.E. SPECT/CT imaging of high-risk atherosclerotic plaques using integrin-binding RGD dimer peptides. Sci. Rep. 2015, 5:11752.
30. Capello A., Krenning E.P., Bernard B.F., Breeman W.A., Erion J.L., de Jong M. Anticancer activity of targeted proapoptotic peptides. J. Nucl. Med. 2006, 47:122-129.
31. Li Z.B., Wu Z., Chen K., Ryu E.K., Chen X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med. 2008, 49:453-461.
32. van Hagen P.M., Breeman W.A., Reubi J.C., Postema P.T., van den Anker-Lugtenburg P.J., Kwekkeboom D.J., Laissue J., Waser B., Lamberts S.W., Visser T.J., Krenning E.P. Visualization of the thymus by substance P receptor scintigraphy in man. Eur. J. Nucl. Med. 1996, 23:1508-1513.
33. Kneifel S., Cordier D., Good S., Ionescu M.C., Ghaffari A., Hofer S., Kretzschmar M., Tolnay M., Apostolidis C., Waser B., Arnold M., Mueller-Brand J., Maecke H.R., Reubi J.C., Merlo A. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin. Cancer Res. 2006, 12:3843-3850.
34. Cordier D., Forrer F., Kneifel S., Sailer M., Mariani L., Macke H., Muller-Brand J., Merlo A. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P-results from a phase I study. J. Neurooncol. 2010, 100:129-136.
35. Theodore P. All about Albumin 1995, Elsevier, Amsterdam.
36. Sand K.M., Bern M., Nilsen J., Noordzij H.T., Sandlie I., Andersen J.T. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front. Immunol. 2014, 5:682.
37. Baker M.E. Albumin, steroid hormones and the origin of vertebrates. J. Endocrinol. 2002, 175:121-127.
38. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
39. Waldmann T.A. Gastrointestinal protein loss demonstrated by Cr-51-labelled albumin. Lancet 1961, 2:121-123.
40. Divgi C.R., Lisann N.M., Yeh S.D., Benua R.S. Technetium-99m albumin scintigraphy in the diagnosis of protein-losing enteropathy. J. Nucl. Med. 1986, 27:1710-1712.
41. Nyman D.W., Campbell K.J., Hersh E., Long K., Richardson K., Trieu V., Desai N., Hawkins M.J., Von Hoff D.D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 2005, 23:7785-7793.
42. Merlot A.M., Kalinowski D.S., Richardson D.R. Unraveling the mysteries of serum albumin-more than just a serum protein. Front. Physiol. 2014, 5:299.
43. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Rel. 2008, 132:171-183.
44. Boyer C., Whittaker M.R., Bulmus V., Liu J., Davis T.P. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Mater. 2010, 2:23-30.
45. Di Marco M., Sadun C., Port M., Guilbert I., Couvreur P., Dubernet C. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int. J. Nanomed. 2007, 2:609-622.
46. Bronzino J.D., Peterson D.R. Biomedical signals, imaging, and informatics. Magnetic Resonance Imaging of Atherosclerosis 2015, 16-33. CRC Press, Boca Raton (FL). fourth ed. C. Yuan, W.S. Kerwin, G. Canton, J. Wang, H. Chen, N. Balu (Eds.).
47. Widder K.J., Morris R.M., Poore G., Howard D.P., Senyei A.E. Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:579-581.
48. Yang X., Grailer J.J., Rowland I.J., Javadi A., Hurley S.A., Matson V.Z., Steeber D.A., Gong S. Multifunctional stable and pH-responsive polymer vesicles formed by heterofunctional triblock copolymer for targeted anticancer drug delivery and ultrasensitive MR imaging. ACS Nano 2010, 4:6805-6817.
49. Hwu J.R., Lin Y.S., Josephrajan T., Hsu M.H., Cheng F.Y., Yeh C.S., Su W.C., Shieh D.B. Targeted Paclitaxel by conjugation to iron oxide and gold nanoparticles. J. Am. Chem. Soc. 2009, 131:66-68.
50. Lammers T., Kiessling F., Hennink W.E., Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol. Pharm. 2010, 7:1899-1912.
51. Fan C.H., Ting C.Y., Lin H.J., Wang C.H., Liu H.L., Yen T.C., Yeh C.K. SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials 2013, 34:3706-3715.
52. Lee C.M., Cheong S.J., Kim E.M., Lim S.T., Jeong Y.Y., Sohn M.H., Jeong H.J. Nonpolymeric surface-coated iron oxide nanoparticles for in vivo molecular imaging: biodegradation, biocompatibility, and multiplatform. J. Nucl. Med. 2013, 54:1974-1980.
53. Zhou H., Hou X., Liu Y., Zhao T., Shang Q., Tang J., Liu J., Wang Y., Wu Q., Luo Z., Wang H., Chen C. Superstable magnetic nanoparticles in conjugation with near-infrared dye as a multimodal theranostic platform. ACS Appl. Mater. Interfaces 2016, 8:4424-4433.
54. Lee C.M., Jang D., Kim J., Cheong S.J., Kim E.M., Jeong M.H., Kim S.H., Kim D.W., Lim S.T., Sohn M.H., Jeong Y.Y., Jeong H.J. Oleyl-chitosan nanoparticles based on a dual probe for optical/MR imaging in vivo. Bioconjug. Chem. 2011, 22:186-192.
55. Frens G. Controlled nucleation for the regulation of particle size in monodisperse gold suspensions. Nat. Phys. Sci. 1972, 241:20-22.
56. Hwang S., Nam J., Jung S., Song J., Doh H., Kim S. Gold nanoparticle-mediated photothermal therapy: current status and future perspective. Nanomedicine (Lond) 2014, 9:2003-2022.
57. Huang X., El-Sayeda M.A. Plasmonic photo-thermal therapy (PPTT). Alexandria J. Med. 2011, 47:1-9.
58. Li Z., Huang H., Tang S., Li Y., Yu X.F., Wang H., Li P., Sun Z., Zhang H., Liu C., Chu P.K. Small gold nanorods laden macrophages for enhanced tumor coverage in photothermal therapy. Biomaterials 2016, 74:144-154.
59. Piao J.G., Wang L., Gao F., You Y.Z., Xiong Y., Yang L. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 2014, 8:10414-10425.
60. Rengan A.K., Bukhari A.B., Pradhan A., Malhotra R., Banerjee R., Srivastava R., De A. In vivo analysis of biodegradable liposome gold nanoparticles as efficient agents for photothermal therapy of cancer. Nano Lett. 2015, 15:842-848.
61. Ng Q.K., Olariu C.I., Yaffee M., Taelman V.F., Marincek N., Krause T., Meier L., Walter M.A. Indium-111 labeled gold nanoparticles for in-vivo molecular targeting. Biomaterials 2014, 35:7050-7057.
62. Zhu J., Chin J., Wangler C., Wangler B., Lennox R.B., Schirrmacher R. Rapid (18)F-labeling and loading of PEGylated gold nanoparticles for in vivo applications. Bioconjug. Chem. 2014, 25:1143-1150.
63. Vilchis-Juarez A., Ferro-Flores G., Santos-Cuevas C., Morales-Avila E., Ocampo-Garcia B., Diaz-Nieto L., Luna-Gutierrez M., Jimenez-Mancilla N., Pedraza-Lopez M., Gomez-Olivan L. Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice. J. Biomed. Nanotechnol. 2014, 10:393-404.
64. Murray C.B., Norris D.J., Bawendi M.G. Synthesis and characterization of nearly monodisperse CdE (E = sulfur, selenium, tellurium) semiconductor nanocrystallites. J. Am. Chem. Soc. 1993, 115:8706-8715.
65. Chung Leland W.K., Isaacs W.B., Simons J.W. Prostate cancer: biology, genetics, and the new therapeutics. Quantum Dot Nanotechnology for Prostate cancer Research 2007, 231. Human Press, New Jersey. X. Gao, Y. Xing, W.K. Chung Leland, S. Nie (Eds.).
66. Savla R., Taratula O., Garbuzenko O., Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control. Rel. 2011, 153:16-22.
67. Han H.S., Niemeyer E., Huang Y., Kamoun W.S., Martin J.D., Bhaumik J., Chen Y., Roberge S., Cui J., Martin M.R., Fukumura D., Jain R.K., Bawendi M.G., Duda D.G. Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:1350-1355.
68. Sonali S., Singh R.P., Singh N., Sharma G., Vijayakumar M.R., Koch B., Singh S., Singh U., Dash D., Pandey B.L., Muthu M.S. Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics. Drug Deliv. 2016, 1-11.
69. Zhu H., Zhang S., Ling Y., Meng G., Yang Y., Zhang W. pH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery. J. Control. Rel. 2015, 220:529-544.
70. Liang X., Shi B., Wang K., Fan M., Jiao D., Ao J., Song N., Wang C., Gu J., Li Z. Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery. Biomaterials 2016, 82:194-207.
71. Yin W., Kimbrough C.W., Gomez-Gutierrez J.G., Burns C.T., Chuong P., Grizzle W.E., McNally L.R. Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomography. J. Nanobiotechnol. 2015, 13:90.
72. Jeong H.S., Lee C.M., Cheong S.J., Kim E.M., Hwang H., Na K.S., Lim S.T., Sohn M.H., Jeong H.J. The effect of mannosylation of liposome-encapsulated indocyanine green on imaging of sentinel lymph node. J. Liposome Res. 2013, 23:291-297.
73. Jeong H.S., Na K.S., Hwang H., Oh P.S., Kim D.H., Lim S.T., Sohn M.H., Jeong H.J. Effect of space length of mannose ligand on uptake of mannosylated liposome in RAW 264.7 cells: in vitro and in vivo studies. J. Biomed. Mater. Res. A 2014, 102:4545-4553.
74. Fischbach M.A., Bluestone J.A., Lim W.A. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med. 2013, 5:179ps7.
75. Kim J.E., Ahn B.C., Lee H.W., Hwang M.H., Shin S.H., Lee S.W., Sung Y.K., Lee J. In vivo monitoring of survival and proliferation of hair stem cells in a hair follicle generation animal model. Mol. Imaging 2013, 12:310-317.
76. Yaghoubi S.S., Jensen M.C., Satyamurthy N., Budhiraja S., Paik D., Czernin J., Gambhir S.S. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat. Clin. Pract. Oncol. 2009, 6:53-58.
77. Ahn B.C. Applications of molecular imaging in drug discovery and development process. Curr. Pharm. Biotechnol. 2011, 12:459-468.
78. Ahn B.C., Parashurama N., Patel M., Ziv K., Bhaumik S., Yaghoubi S.S., Paulmurugan R., Gambhir S.S. Noninvasive reporter gene imaging of human Oct4 (pluripotency) dynamics during the differentiation of embryonic stem cells in living subjects. Mol. Imaging Biol. 2014, 16:865-876.
79. Lee H.W., Yoon S.Y., Singh T.D., Choi Y.J., Lee H.J., Park J.Y., Jeong S.Y., Lee S.W., Ha J.H., Ahn B.C., Jeon Y.H., Lee J. Tracking of dendritic cell migration into lymph nodes using molecular imaging with sodium iodide symporter and enhanced firefly luciferase genes. Sci. Rep. 2015, 14:9865.
80. Creusot R.J., Yaghoubi S.S., Chang P., Chia J., Contag C.H., Gambhir S.S., Fathman C.G. Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells. Blood 2009, 113:6638-6647.
81. Yu X., Chen D., Zhang Y., Wu X., Huang Z., Zhou H., Zhang Y., Zhang Z. Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke. J. Neurol. Sci. 2012, 316:141-149.
82. Zhao J., Vykoukal J., Abdelsalam M., Recio-Boiles A., Huang Q., Qiao Y., Singhana B., Wallace M., Avritscher R., Melancon M.P. Stem cell-mediated delivery of SPIO-loaded gold nanoparticles for the theranosis of liver injury and hepatocellular carcinoma. Nanotechnology 2014, 25:405101.